Inovio Pharmaceuticals Inc said its COVID-19 vaccine candidate was safe, well-tolerated and produced immune response against the new coronavirus in a mid-stage clinical trial, sending the drug developer’s shares up over 3%.
Inovio says COVID-19 vaccine candidate safe, effective in mid-stage trial
2021-05-10T12:11:40-04:00May 10th, 2021|